Vanda Pharmaceuticals (VNDA) Income towards Parent Company: 2009-2024
Historic Income towards Parent Company for Vanda Pharmaceuticals (VNDA) over the last 16 years, with Dec 2024 value amounting to -$18.9 million.
- Vanda Pharmaceuticals' Income towards Parent Company fell 324.23% to -$22.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$84.2 million, marking a year-over-year decrease of 413.85%. This contributed to the annual value of -$18.9 million for FY2024, which is 853.29% down from last year.
- Per Vanda Pharmaceuticals' latest filing, its Income towards Parent Company stood at -$18.9 million for FY2024, which was down 853.29% from $2.5 million recorded in FY2023.
- In the past 5 years, Vanda Pharmaceuticals' Income towards Parent Company registered a high of $33.2 million during FY2021, and its lowest value of -$18.9 million during FY2024.
- Over the past 3 years, Vanda Pharmaceuticals' median Income towards Parent Company value was $2.5 million (recorded in 2023), while the average stood at -$3.4 million.
- Its Income towards Parent Company has fluctuated over the past 5 years, first soared by 42.06% in 2021, then plummeted by 853.29% in 2024.
- Yearly analysis of 5 years shows Vanda Pharmaceuticals' Income towards Parent Company stood at $23.3 million in 2020, then soared by 42.06% to $33.2 million in 2021, then tumbled by 81.07% to $6.3 million in 2022, then slumped by 60.02% to $2.5 million in 2023, then slumped by 853.29% to -$18.9 million in 2024.